Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 28 → 29·20:24, 25 May 2025
Difference between revision 28 and revision 29 of Shanghai Wibson Biotechnology. 3 lines changed; the page grew by 229 bytes.
| Revision 28 — 08:26, 17 May 2025 Peptide_Pete (talk) add category 6,586 bytes ±0 | Revision 29 — 20:24, 25 May 2025 FormularyFrida (talk) label community tally as self-reported 6,815 bytes +229 | ||
|---|---|---|---|
| 49 | The catalogue is broadly the sector standard and does not distinguish the organisation from its comparators, which is itself a relevant fact for a reader trying to tell them apart.{{r|selfpub}} | 49 | The catalogue is broadly the sector standard and does not distinguish the organisation from its comparators, which is itself a relevant fact for a reader trying to tell them apart.{{r|selfpub}} |
| 50 | 50 | ||
| + | 51 | == Independent testing record == | |
| + | 52 | Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties.{{r|reports}} | |
| + | 53 | ||
| 51 | == References == | 54 | == References == |
| 52 | {{reflist}} | 55 | {{reflist}} |